Champions Oncology, Inc. services
Research Services & Partnering - Preclinical Testing Platforms
Analytical Endpoint Testing
Champions Oncology’s Analytical Testing platforms can be used to gather additional data at the endpoint of a preclinical model or ex vivo assay. Using multiplex cytokine assays with flow cytometry readouts, immune cell cytokine intracellular and extracellular staining upon activation can be assessed. Champions Oncology can also collect tissues from your in vivo studies and evaluate pathological changes throughout the tissue and/or the tumor itself using Immunohistochemistry (IHC) and other plate-based platforms (i.e. Luminex/ELISA platforms).
Screen Enrollment
Champions Oncology has created screens that enroll each month in either In vivo, Ex Vivo or In vitro platforms. These screens allow for a significant cost savings compared to running stand-alone studies as well as provide free access to Standard of Care response data and other characterization data for each model. Check back frequently to learn more about each screen and to enroll in any active screens.
Research Services & Partnering - Translational Research - Immuno-Oncology Platforms
Autologous Tumor Infiltrating Lymphocyte (TIL) Platform
Champions Oncology`s ex vivo 3D co-culture platform for Immuno-Oncology therapeutic testing. Champions Oncology has launched an innovative new platform enabling Immuno-Oncology researchers the ability to test their therapeutics in a 3D organoid assay that can mimic mechanism of action. The Autologous TIL platform is an ex vivo 3D co-culture platform developed and optimized to interrogate the responses of your Immuno-Oncology drugs with a tumor-specific microenvironment in only 4 days using PDX-O (patient-derived xenograft organoids) collected with matched, autologous TIL samples.
Autologous AML Platform
Champions Oncology`s ex vivo AML co-culture platform for Immuno-Oncology therapeutic testing. Champions Oncology has launched an innovative new platform enabling Acute Myeloid Leukemia (AML) researchers the ability to better understand their therapeutic mechanism of action. The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology drugs in only 4 days using primary patient specimens.
Research Services & Partnering - Clinical Trial Solutions
Clinical Flow Cytometry
Champions Oncology’s clinical flow cytometry services are implemented using fully optimized and validated human panels developed to be customizable to meet your clinical trial needs. Champions Oncology leads the industry in clinical flow cytometry expertise and innovative technology that provides you with the highest quality, complex computational results with the ability to interrogate up to 26 parameters on each individual cell simultaneously within every patient sample.
Others
Driving Oncology Research Services
Champions Oncology is transforming drug discovery and development through our integrated scientific approach. Our expert team works to improve cancer outcomes each day for our research partners and ultimately patients across the globe.
Discovery Services
Champions` Discovery Services leverages the Lumin Analytic Engine and rapid validation workflows to identify novel therapeutic targets and/or biomarkers of resistance.